NDC product
INJECTION, SOLUTION · AstraZeneca AB
NDC 17228-4611 · AstraZeneca AB
Key facts
| Product NDC | 17228-4611 |
|---|---|
| Nonproprietary name | Durvalumab |
| Substances | DURVALUMAB |
| Dosage form | INJECTION, SOLUTION |
| Labeler | AstraZeneca AB |
| Product type | DRUG FOR FURTHER PROCESSING |
| Marketing category | DRUG FOR FURTHER PROCESSING |
| Marketing start | Jan 1, 2020 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: